Brief News | Su Dehui, Deputy Party Secretary, Vice Chairman and General Manager of Hunan Pharmaceutical Development Investment Group, Visits the Company for Research

On December 13, Su Dehui, Deputy Party Secretary, Vice Chairman, and General Manager of the Group, led a delegation to conduct an on-site inspection of the company to assess its production and operational status. The inspection was accompanied by Leng Ying, Director of the Group's Technology Innovation Department, and Wang Jiansong, Deputy Director of the Party-Mass Affairs Department. The company's Chairman Shen Fanshun, General Manager Tan Feng, and other leadership members also participated in the visit.

At the meeting, Shen Fanshun delivered a detailed report to the research team on the progress of key tasks this year, existing challenges, and the objectives and concrete measures for next year. Since the beginning of the year, the company has successfully transformed its flagship products, steadily enhanced brand recognition, achieved remarkable milestones in marketing strategies, made continuous breakthroughs in technological innovation, and optimized internal management. In the next phase, the company will align with the group's strategic plan and overall deployment, adopt a problem-oriented approach, focus on key priorities, set clear benchmarks, and implement comprehensive measures to strengthen core competitiveness. The goal is to establish the company as a top-tier innovative traditional Chinese medicine enterprise in the province.

Su Dehui commended the company's achievements over the past year. He emphasized that the company has undertaken substantial initiatives for long-term development this year, which hold significant strategic value. Since the launch of the thematic education campaign, the company has witnessed remarkable progress and achieved commendable results. All employees must maintain confidence and implement concrete measures to solidify its position as the provincial leader in the new-type Chinese herbal decoction pieces industry. Regarding future work, he outlined six key priorities: 1) As a subsidiary of the pharmaceutical group, the company must balance current and future objectives while embracing greater responsibilities; 2) Further optimize operations by identifying growth bottlenecks, developing actionable plans with strong execution capabilities, and ensuring thorough implementation; 3) Enhance talent development by actively recruiting professionals and optimizing the human resource structure; 4) Innovation and reform drive corporate growth, requiring thorough market analysis for project approvals rather than chasing trends; 5) Prioritize marketing strategies aligned with market demands to deliver better results; 6) Maintain top priority for production safety, ensuring strict compliance with stability maintenance and environmental protection protocols; 7) Uphold Party leadership through integrity-building initiatives and deepen the integration of Party work with business operations.
-
2025-11-11
Good News | The company has been named the first enterprise on the Technology Transfer Board of Hunan Equity Exchange
-
2025-11-11
Good News | Chun Guang Jiu Hui Awarded as Green Factory in Hunan Province
-
2025-08-13
Preview|The First National Academic Exchange Conference of Chun Guang Jiu Hui and the New Book, New Product and New Achievement Release Conference
Back





